Inflammatory diseases: Integrating biosimilars into clinical practice

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 6, 2015, Pages S16-S21

  Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

biologic; biosimilar; clinical practice; comparability; extrapolation; guidelines; immunogenicity; inflammatory disorders; innovator; interchangeability; labeling; naming; pharmacodynamics; pharmacokinetics; pharmacovigilance; reference product; regulations; safety; surveillance

Indexed keywords

BIOSIMILAR AGENT; INFLIXIMAB;

ARTICLE; CHRONIC DISEASE; CLINICAL PRACTICE; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLAMMATORY DISEASE; PATIENT SELECTION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOLOGIST; ARTHRITIS; EUROPE; INFLAMMATORY BOWEL DISEASES; PSORIASIS; SPONDYLITIS, ANKYLOSING; UNITED STATES;

ARTHRITIS; BIOSIMILAR PHARMACEUTICALS; EUROPE; HUMANS; INFLAMMATORY BOWEL DISEASES; PRACTICE GUIDELINES AS TOPIC; PSORIASIS; SPONDYLITIS, ANKYLOSING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84953376177     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2015.04.003     Document Type: Article

References (61)

1. El-Gabalawy, H., Guenther, L.C., Bernstein, C.N., Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl 85 (2010), 2–10.
2. Kay, J., Smolen, J.S., Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 72 (2013), 1589–1593.
3. Scheinberg, M.A., Kay, J., The advent of biosimilar therapies in rheumatology—“O brave new world”. Nat Rev Rheumatol 8 (2012), 430–436.
4. Molodecky, N.A., Soon, I.S., Rabi, D.M., Ghali, W.A., Ferris, M., Chernoff, G., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142 (2012), 46–54.
5. Billiet, T., Rutgeerts, P., Ferrante, M., Van, A.G., Vermeire, S., Targeting TNF-alpha for the treatment of inflammatory bowel disease. Expert Opin Biol Ther 14 (2014), 75–101.
6. Baraliakos, X., Braun, J., Biologic therapies for spondyloarthritis: what is new?. Curr Rheumatol Rep 14 (2012), 422–427.
7. Strand, V., Cronstein, B., Biosimilars: how similar?. Intern Med J 44 (2014), 218–223.
8. Singh, J.A., Furst, D.E., Bharat, A., Curtis, J.R., Kavanaugh, A.F., Krermer, J.M., et al. update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012:64 (2012), 625–639.
9. Ahmad, A., Cowling, T., Laverty, A., Kang, J.Y., Majeed, A., Pollok, R., Changing trends in IBD hospital admissions and management in England, 2001-2 to 2010-11. Poster P0270. United European Gastroenterol J, 2, 2014, A204.
10. Bejarano, V., Quinn, M., Conaghan, P.G., Reece, R., Keenan, A.M., Walker, D., et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 59 (2008), 1467–1474.
11. Golovics, P.A., Balint, A., Mandel, M., Vegh, Z., Mohas, A., Szilagyi, B., et al. Hospitalization rate before and after anti-TNF therapy: Hospitalization rates are associated with time to anti-TNF therapy. Poster P1420. United European Gastroenterol J, 2, 2014, A518.
12. Cuadrado, M.J., Sciascia, S., Bosch, X., Khamashta, M.A., Ramos-Casals, M., Is it time for biosimilars in autoimmune diseases?. Autoimmun Rev 12 (2013), 954–957.
13. Lapadula, G., Ferraccioli, G.F., Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. Clin Exp Rheumatol 30 (2012), S102–S106.
14. Dorner, T., Strand, V., Castaneda-Hernandez, G., Ferraccioli, G., Isaacs, J.D., Kvien, T.K., et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 72 (2013), 322–328.
15. Mysler, E., Scheinberg, M., Biosimilars in rheumatology: a view from Latin America. Clin Rheumatol 31 (2012), 1279–1280.
16. Scheinberg, M.A., Azevedo, V.F., Biosimilars in rheumatology: perspective and concerns. Rheumatology (Oxford) 53 (2014), 389–390.
17. European Medicines Agency. Guideline on similar biological medicinal products, 〈http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf〉; 2005 [accessed 18.12.13].
18. European Medicines Agency. European public assessment reports—Biosimilars, 〈http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&keyword=Enter keywords&searchType=name&alreadyLoaded=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&jsenabled=false&searchGenericType=biosimilars&orderBy=authDate&pageNo=1〉; 2014 [accessed 22.05.14].
19. World Health Organization. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs), 〈http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf〉; 2009 [accessed 25.02.14].
20. US Food and Drug Administration. Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product, 〈http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf〉; 2012 [accessed 21.05.14].
21. US Food and Drug Administration. Guidance for industry. Quality considerations in demonstrating biosimilarity to a reference protein product, 〈http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf〉; 2012 [accessed 21.05.14].
22. US Food and Drug Administration. Guidance for industry. Biosimilars: questions and answers regarding implementation of the Biological Price Competition and Innovation Act of 2009, 〈http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm259797.htm〉; 2012 [accessed 25.02.14].
23. US Food and Drug Administration. Guidance for industry. Formal meetings between the FDA and biosimilar biological product sponsors or applicants, 〈http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM345649.pdf〉; 2013 [accessed 25.02.14].
24. US Food and Drug Administration. Guidance for industry. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product, 〈http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf〉; 2014 [accessed 19.05.14].
25. US Food and Drug Administration. Guidance for industry. Reference product exclusivity for biological products filed under 351(a) of the PHS Act, 〈http://www.fdanews.com/ext/resources/files/08/08-04-14-BiosimilarsExclusivityGuidance.pdf〉; 2014 [accessed 19.08.14].
26. Schiestl, M., Stangler, T., Torella, C., Cepeljnik, T., Toll, H., Grau, R., Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 29 (2011), 310–312.
27. Mellstedt, H., Niederwieser, D., Ludwig, H., The challenge of biosimilars. Ann Oncol 19 (2008), 411–419.
28. Ryan, A.M., Frontiers in nonclinical drug development: biosimilars. Vet Pathol, 2014 〈http://dx.doi.org/10.1177/0300985814547282〉.
29. Schneider, C.K., Biosimilars in rheumatology: the wind of change. Ann Rheum Dis 72 (2013), 315–318.
30. Berghout, A., Clinical programs in the development of similar biotherapeutic products: rationale and general principles. Biologicals 39 (2011), 293–296.
31. European Medicines Agency. Guideline on similar biological medical products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, 〈http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144124.pdf〉; 2013 [accessed 14.01.14].
32. Lee, H., Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?. AAPS J 16 (2014), 22–26.
33. European Medicines Agency. Assessment report. Inflectra, 〈http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf〉; 2013 [accessed 08.04.14].
34. European Medicines Agency. Assessment report. Remsima, 〈http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf〉; 2013 [accessed 09.04.14].
35. Health Canada Summary basis of decision (SBD) for Inflectra, 〈http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_inflectra_159493-eng.php〉; 2014 [accessed 09.04.14].
36. Health Canada. Summary basis of decision (SBD) for Remsima, 〈http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_remsima_160195-eng.php〉; 2014 [accessed 09.04.14].
37. Biosimilar infliximab approved in Japan, but not with full extrapolation. The Biosimilarz Blog! 〈http://www.biosimilarz.com/?p=535〉; 2014 [accessed 13.01.15].
38. Arguelles-Arias, F., Barreiro-de-Acosta, M., Carballo, F., Hinojosa, J., Tejerina, T., Joint position statement by Spanish Society of Gastroenterology and Spanish Society of Pharmacology on biosimilar therapy for inflammatory bowel disease. Rev Esp Enferm Dig 105 (2013), 37–43.
39. Danese, S., Gomollon, F., ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 7 (2013), 586–589.
40. O׳Dell JR. American College of Rheumatology. Re: draft guidances relating to the development of biosimilar products; public hearing; request for comments; Docket no. FDA-2011-D-0618, 〈http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&ved=0CDwQFjAC&url=http%3A%2F%2Fwww.rheumatology.org%2FAdvocacy%2FLetters%2F2012%2FFDA_Biosimilar_Draft_Guidance%2F&ei=gEJFU4KrDsXL2gXEjIDoBQ&usg=AFQjCNE7WVKvF4OHsi_YlPtIx68UHeYQBg〉; 2012 [accessed 09.04.14].
41. Polinski, J.M., Mohr, P.E., Johnson, L., Impact of medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis. Arthritis Rheum 61 (2009), 745–754.
42. Editorial, The INN crowd. Nat Biotechnol, 31, 2013, 1055.
43. World Health Organization. 57th Consultation on International Nonproprietary Names for Pharmaceutical Substances, Geneva, 22–24 October 2013. Executive Summary, 〈http://www.who.int/medicines/services/inn/57th_Executive_Summary.pdf?ua=1〉; 2013 [accessed 02.05.14].
44. World Health Organization. International nonproprietary names, 〈http://www.who.int/medicines/services/inn/en/〉; 2014 [accessed 22.05.14].
45. World Health Organization. Biological Qualifier. An INN proposal, 〈http://www.who.int/medicines/services/inn/bq_innproposal201407.pdf〉; 2014 [accessed 22.12.14].
46. American College of Rheumatology. American College of Rheumatology position statement: biosimilars, 〈https://www.rheumatology.org/Practice/Clinical/Position/Position_Statements/〉; 2011 [accessed 14.05.14].
47. American Academy of Dermatology. Position statement on generic therapeutic & biosimilar substitution, 〈http://www.aad.org/Forms/Policies/Uploads/PS/PS-Generic%20Therapeutic%20and%20%20Biosimilar%20Substitution.pdf〉; 2013 [accessed 09.05.14].
48. Kay, J., Biosimilars: a regulatory perspective from America. Arthritis Res Ther, 13, 2011, 112.
49. Weise, M., Bielsky, M.C., De Smet, K., Ehmann, F., Ekman, N., Giezen, T.J., et al. Biosimilars: what clinicians should know. Blood 120 (2012), 5111–5117.
50. Christl L. US Food and Drug Administration. FDA׳s overview of the regulatory guidance for the development and approval of biosimilar products in the US, 〈http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM428732.pdf〉; 2015 [accessed 13.01.15].
51. Kanter, J., Feldman, R., Understanding and incentivizing biosimilars. Hastings Law J 64 (2012), 57–82.
52. Congress of the United States of America. Patient Protection and Affordable Care Act, 〈http://www.gpo.gov/fdsys/pkg/PLAW-111publ148/pdf/PLAW-111publ148.pdf〉; 2010 [accessed 18.12.13].
53. World Health Organization. Pharmacovigilance, 〈http://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/〉; 2014 [accessed 14.05.14].
54. US Food and Drug Administration. Guidance for industry. Good pharmacovigilance practices and pharmacoepidemiologic assessment, 〈http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126834.pdf〉; 2005 [accessed 01.05.14].
55. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module I Pharmacovigilance systems and their quality systems, 〈http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129132.pdf〉; 2012 [accessed 14.05.14].
56. European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies—non-clinical and clinical issues, 〈http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf〉; 2012 [accessed 19.12.13].
57. European Medicines Agency. Remicade. Annex I. Summary of product characteristics, 〈http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf〉; 2009 [accessed 17.07.14].
58. Zelenetz, A.D., Ahmed, I., Braud, E.L., Cross, J.D., Davenport-Ennis, N., Dickinson, B.D., et al. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw 9 (2011), S1–22.
59. Clarkston Consulting. Biosimilars are coming. Are you ready? 〈http://www.clarkstonconsulting.com/wp-content/uploads/2013/06/Insights_Biosimilars_US20133.pdf〉; 2013 [accessed 27.02.14].
60. Danese S, Fiorino G, Michetti P. Are I.B.D. Specialists aware of biosimilar monoclonal antibodies? Results from a survey among ECCO members. Paper presented at 9th Congress of European Crohn׳s and Colitis Organization. Copenhagen, Denmark; February 2014. P. 20–2.
61. Azevedo, V.F., Felippe, L.R., Machado, D.M., Opinion of some Brazilian rheumatologists about biosimilars. Rev Bras Reumatol 51 (2011), 667–671.